Kazuyoshi Shigehara

Kanazawa, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 190 publications

EFFICACY OF KEISHIBUKURYOGAN FOR HOT FLASH ASSOCIATED WITH HORMONE THERAPY IN PATIENTS WITH PROSTATE CANCER

EFFICACY OF KEISHIBUKURYOGAN FOR HOT FLASH ASSOCIATED WITH HORMONE THERAPY IN PATIENTS WITH PROSTATE CANCER

Journal: Hinyokika kiyo. Acta urologica Japonica

Published: September 04, 2026

Stage-Specific Temporal Trends in Treatment Patterns and Overall Survival in Prostate Cancer: A Multicentre Real-World Cohort Study From KAMU-ON.

Stage-Specific Temporal Trends in Treatment Patterns and Overall Survival in Prostate Cancer: A Multicentre Real-World Cohort Study From KAMU-ON.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: July 06, 2026

Comparative Prognostic Impact of Two-Dimensional and Three-Dimensional Computed Tomography-Based Sarcopenia Indices in Metastatic Castration-Sensitive Prostate Cancer.

Comparative Prognostic Impact of Two-Dimensional and Three-Dimensional Computed Tomography-Based Sarcopenia Indices in Metastatic Castration-Sensitive Prostate Cancer.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: June 14, 2026

Integrating NCCN and LATITUDE in metastatic castration-sensitive prostate cancer: a TITAN analysis.

Integrating NCCN and LATITUDE in metastatic castration-sensitive prostate cancer: a TITAN analysis.

Journal: World journal of urology

Published: June 01, 2026

Survival Benefit of ARSI Therapy in Japanese mCSPC: A Systematic Review and Meta-Analysis.

Survival Benefit of ARSI Therapy in Japanese mCSPC: A Systematic Review and Meta-Analysis.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: May 22, 2026

Efficacy and Safety of Two-Weekly Enfortumab Vedotin in Combination With Pembrolizumab for Advanced Urothelial Carcinoma.

Efficacy and Safety of Two-Weekly Enfortumab Vedotin in Combination With Pembrolizumab for Advanced Urothelial Carcinoma.

Journal: Asia-Pacific journal of clinical oncology

Published: April 22, 2026

The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC.

The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC.

Journal: The Prostate

Published: April 22, 2026

Efficacy of Testosterone Replacement Therapy Combined With Exercise on Body Composition in Hypogonadal Men.

Efficacy of Testosterone Replacement Therapy Combined With Exercise on Body Composition in Hypogonadal Men.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: April 02, 2026

Quality-of-Life in CRPC Patients Treated With Enzalutamide Versus Abiraterone: Impact of Standard and Modified Dosing.

Quality-of-Life in CRPC Patients Treated With Enzalutamide Versus Abiraterone: Impact of Standard and Modified Dosing.

Journal: Clinical genitourinary cancer

Published: March 27, 2026

Triplet Therapy (Androgen Deprivation Therapy + Darolutamide + Biweekly Docetaxel) for High-risk Metastatic Castration-sensitive Prostate Cancer (TRIC Study): A Study Protocol for Open-labelled Single-Arm Phase II Clinical Trial.

Triplet Therapy (Androgen Deprivation Therapy + Darolutamide + Biweekly Docetaxel) for High-risk Metastatic Castration-sensitive Prostate Cancer (TRIC Study): A Study Protocol for Open-labelled Single-Arm Phase II Clinical Trial.

Journal: JMA journal

Published: January 29, 2026

Prognostic Significance of Radiographic Progression at Metastatic Castration-Resistant Prostate Cancer Diagnosis.

Prognostic Significance of Radiographic Progression at Metastatic Castration-Resistant Prostate Cancer Diagnosis.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: January 22, 2026

Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa.

Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: January 15, 2026

Showing 1-12 of 190

Last Updated: 09/26/2026